


## Supplementary information, Figure S1



**Fig. S1** FVII, FIX, and FX exhibit antibacterial activity. **a** Sequence alignments of the LC of FVII with the homologous FIX and FX. Sequence alignment was carried out using Vector NTI Advance 11 (Invitrogen). **b** Growth kinetic measurement of *E. coli* DH5 $\alpha$  exposed to FVII (100  $\mu$ g/ml), FIX (100  $\mu$ g/ml) and FX (200  $\mu$ g/ml) without or with addition of specific antibody (anti-FVII Ab, 100  $\mu$ g/ml; anti-FIX Ab, 100  $\mu$ g/ml; anti-FX Ab, 200  $\mu$ g/ml). Untreated bacteria were included. Data represent mean values from five independent experiments. **c** PT (left) and aPTT (right) of the antibody-infused mice. The following antibodies (dose per mouse in parentheses), with saline as a blank control, were investigated in groups of eight mice: anti-FVII Ab (1  $\mu$ g), anti-FIX Ab (8  $\mu$ g), anti-FX Ab (8  $\mu$ g), Ab combination (1  $\mu$ g of anti-FVII Ab, 8  $\mu$ g of anti-FIX Ab and 8  $\mu$ g of anti-FX Ab), normal goat IgG (16  $\mu$ g) and normal rabbit IgG (16  $\mu$ g). PT and aPTT were determined after 3 h of the antibody infusion.